More Articles

Positive trial results for Lannett’s insulin biosimilar Biosimilars/Research | Posted 17/01/2020

US firm Lannett has completed a successful trial of their candidate insulin biosimilar, which was compared to Sanofi’s blockbuster insulin product Lantus.

FDA approves MS and prostate generics Generics/News | Posted 17/01/2020

The US Food and Drug Administration (FDA) in December 2019 approved the first generics of Gilenya (fingolimod) for multiple sclerosis (MS) and Rapaflo (silodosin) for benign prostatic hyperplasia.

EC workshop on biosimilars focusses on sustainability Reports | Posted 10/01/2020

The European Commission (EC) held its fifth workshop on biosimilars in Brussels, Belgium on 30 October 2019. The focus of this workshop was the sustainability of the biosimilar medicines sector [1].

NeuClone progress with ustekinumab and trastuzumab biosimilars Biosimilars/Research | Posted 10/01/2020

Australian biosimilars firm NeuClone has started a phase I trial of their proposed ustekinumab biosimilar and announced positive results from a trial of their trastuzumab biosimilar.

Non-originator biologicals approved in Russia Biosimilars/General | Posted 10/01/2020

Last update: 10 January 2020In Russia, the regulatory body for the approval of medicines is Russia’s Ministry of Health (Министерство здравоохранения Российской Федерации; Rosminzdrav, Minzdrav).

American College of Physicians makes new recommendations to cut drug spending Generics/Research | Posted 10/01/2020

A paper from the American College of Physicians (ACP) makes a number of policy recommendations to reduce costs of prescription drugs in the US, including annual caps for out-of-pocket spending and...

Analytical similarity assessment of teriparatide biosimilar Terrosa Biosimilars/Research | Posted 10/01/2020

Terrosa and Movymia (both developed under the code name RGB-10), were the first biosimilars of Eli Lilly’s osteoporosis biological Forteo/Forsteo (teriparatide) in Europe. Gedeon Richter and Stada...

Japanese firms to collaborate on Eylea biosimilar Pharma News | Posted 10/01/2020

Japanese pharmaceutical firms Gene Techno Science and Kishi Kasei announced on 2 December 2019 an agreement for the joint development of an aflibercept biosimilar, a treatment for macular degenerat...